Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2015

01.04.2015 | Laboratory Investigation

Prognostic marker analysis in pediatric intracranial ependymomas

verfasst von: Roger E. McLendon, Eric Lipp, Diane Satterfield, Melissa Ehinger, Alan Austin, Debra Fleming, Kathryn Perkinson, Michaela Lefaivre, David Zagzag, Benjamin Wiener, Sri Gururangan, Herbert Fuchs, Henry S. Friedman, James E. Herndon II., Patrick Healy

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Histologic grading methods dependent upon H&E staining review have not been shown to reliably predict survival in children with intracranial ependymomas due to the subjectivity of the analytical methods. We hypothesized that the immunohistochemical detection of MIB-1, Tenascin C, CD34, VEGF, and CA IX may represent objective markers of post-operative survival (Progression Free and Overall Survival; PFS, OS) in these patients. Intracranial ependymomas from patients aged 22 years or less were studied. The original histologic grade was recorded, H&E sections were reviewed for vascular proliferation status, and immunohistochemistry was used to determine MIB-1, Tenascin C, CD34, VEGF, and CA IX status. Based upon the World Health Organization (WHO) grading system, 3 Grade I, 18 Grade II and 9 Grade III ependymomas were studied. Median follow-up time was 9.0 years; median PFS was, 6.1 years. Original WHO grade did not correlate with PFS or OS. Peri-necrotic CA IX localization correlated with PFS (Log rank = 0.0181) and OS (Log rank p = 0.0015). All patients with a CA IX ≤ 5 % total area localization were alive at last follow-up. Perinecrotic CA IX staining was also associated with vascular proliferation (p = 0.006), though not with VEGF expression score. MIB-1 labeling index (LI) correlated with OS (HR 1.06, 95 % CI 1.01, 1.12) and PFS (HR 1.08, 95 % CI 1.02, 1.14). MIB-1 LI and perinecrotic CA IX individually correlated with PFS. The effect of perinecrotic CA IX remained when grade was added to a Cox model predicting PFS. Immunodetection of CA IX and MIB-1 expression are predictive biomarkers for survival in children with posterior fossa ependymomas. These markers represent objective indicators of survival that supplement H&E grading alone.
Literatur
1.
Zurück zum Zitat McLendon RE, Wiestler OD, Kros JM, Korshunov A, Ng H-K (2007) Ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon, pp 72–74 McLendon RE, Wiestler OD, Kros JM, Korshunov A, Ng H-K (2007) Ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon, pp 72–74
2.
Zurück zum Zitat Ng H-K (2006) Ependymoma, subependymoma, and myxopapillary ependymoma. In: McLendon RE, Rosenblum MK, Bigner DD (eds) Russell and Rubinstein’s pathology of tumors of the nervous system. Hodder Arnold, London, pp 201–222CrossRef Ng H-K (2006) Ependymoma, subependymoma, and myxopapillary ependymoma. In: McLendon RE, Rosenblum MK, Bigner DD (eds) Russell and Rubinstein’s pathology of tumors of the nervous system. Hodder Arnold, London, pp 201–222CrossRef
3.
Zurück zum Zitat Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ (2008) The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors. Mod Pathol 21:165–177. doi:10.1038/modpathol.3800999 PubMed Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ (2008) The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors. Mod Pathol 21:165–177. doi:10.​1038/​modpathol.​3800999 PubMed
4.
Zurück zum Zitat Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert, Aldape KD, Collaborative Ependymoma Research N (2013) Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol 23:584–594. doi:10.1111/bpa.12050 CrossRefPubMed Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert, Aldape KD, Collaborative Ependymoma Research N (2013) Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol 23:584–594. doi:10.​1111/​bpa.​12050 CrossRefPubMed
6.
Zurück zum Zitat Preusser M, Heinzl H, Gelpi E, Hoftberger R, Fischer I, Pipp I, Milenkovic I, Wohrer A, Popovici F, Wolfsberger S, Hainfellner JA (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39–47. doi:10.1111/j.1365-2559.2008.03065.x CrossRefPubMed Preusser M, Heinzl H, Gelpi E, Hoftberger R, Fischer I, Pipp I, Milenkovic I, Wohrer A, Popovici F, Wolfsberger S, Hainfellner JA (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39–47. doi:10.​1111/​j.​1365-2559.​2008.​03065.​x CrossRefPubMed
7.
Zurück zum Zitat Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM (2006) Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 106:388–395. doi:10.1002/cncr.21608 CrossRefPubMed Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM (2006) Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 106:388–395. doi:10.​1002/​cncr.​21608 CrossRefPubMed
8.
Zurück zum Zitat Chan AS, Leung SY, Wong MP, Yuen ST, Cheung N, Fan YW, Chung LP (1998) Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22:816–826CrossRefPubMed Chan AS, Leung SY, Wong MP, Yuen ST, Cheung N, Fan YW, Chung LP (1998) Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22:816–826CrossRefPubMed
9.
Zurück zum Zitat Preusser M, Wolfsberger S, Haberler C, Breitschopf H, Czech T, Slavc I, Harris AL, Acker T, Budka H, Hainfellner JA (2005) Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol 109:211–216. doi:10.1007/s00401-004-0938-8 CrossRefPubMed Preusser M, Wolfsberger S, Haberler C, Breitschopf H, Czech T, Slavc I, Harris AL, Acker T, Budka H, Hainfellner JA (2005) Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol 109:211–216. doi:10.​1007/​s00401-004-0938-8 CrossRefPubMed
10.
Zurück zum Zitat Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843–7848CrossRefPubMed Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843–7848CrossRefPubMed
11.
Zurück zum Zitat Gururangan S, Fangusaro J, Poussaint TY, Onar A, Gilbertson R, Packer R, McLendon R, Friedman H, Boyett J, Kun LL (2010) Lack of efficacy of bevacizumab + CPT-11 in children with recurrent ependymoma: a pediatric brain tumor consortium study. In: Pediatric brain tumor consortium spring meeting, 2011 Gururangan S, Fangusaro J, Poussaint TY, Onar A, Gilbertson R, Packer R, McLendon R, Friedman H, Boyett J, Kun LL (2010) Lack of efficacy of bevacizumab + CPT-11 in children with recurrent ependymoma: a pediatric brain tumor consortium study. In: Pediatric brain tumor consortium spring meeting, 2011
12.
Zurück zum Zitat Sathornsumetee S, Cao Y, Marcello JE, Herndon JE II, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271–278. doi:10.1200/JCO.2007.13.3652 CrossRefPubMedCentralPubMed Sathornsumetee S, Cao Y, Marcello JE, Herndon JE II, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271–278. doi:10.​1200/​JCO.​2007.​13.​3652 CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Preusser M, Birner P, Hainfellner JA (2004) Algorithm for the standardized assessment of vascular patterns in glioblastoma specimens. Clin Neuropathol 23:238–240PubMed Preusser M, Birner P, Hainfellner JA (2004) Algorithm for the standardized assessment of vascular patterns in glioblastoma specimens. Clin Neuropathol 23:238–240PubMed
14.
Zurück zum Zitat Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rossler K, Budka H, Harris AL, Hainfellner JA (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133–143CrossRefPubMed Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rossler K, Budka H, Harris AL, Hainfellner JA (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133–143CrossRefPubMed
15.
Zurück zum Zitat Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, Frappaz D, Massimino M, Grill J, Boyett JM, Grundy RG (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10:7. doi:10.1186/1477-5751-10-7 CrossRefPubMedCentralPubMed Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, Frappaz D, Massimino M, Grill J, Boyett JM, Grundy RG (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10:7. doi:10.​1186/​1477-5751-10-7 CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat CBTRUS (2008) Supplement report: primary brain tumors in the United States, 2004. In: Central brain tumor registry of the United States, Hinsdale, IL CBTRUS (2008) Supplement report: primary brain tumors in the United States, 2004. In: Central brain tumor registry of the United States, Hinsdale, IL
17.
22.
Zurück zum Zitat Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473–477. doi:10.1158/1078-0432.CCR-05-0848 CrossRefPubMed Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473–477. doi:10.​1158/​1078-0432.​CCR-05-0848 CrossRefPubMed
24.
Zurück zum Zitat Korshunov A, Golanov A, Timirgaz V (2002) Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 58:255–270CrossRefPubMed Korshunov A, Golanov A, Timirgaz V (2002) Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol 58:255–270CrossRefPubMed
25.
Zurück zum Zitat Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, Wiestler OD (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109–117CrossRefPubMed Pietsch T, Valter MM, Wolf HK, von Deimling A, Huang HJ, Cavenee WK, Wiestler OD (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109–117CrossRefPubMed
Metadaten
Titel
Prognostic marker analysis in pediatric intracranial ependymomas
verfasst von
Roger E. McLendon
Eric Lipp
Diane Satterfield
Melissa Ehinger
Alan Austin
Debra Fleming
Kathryn Perkinson
Michaela Lefaivre
David Zagzag
Benjamin Wiener
Sri Gururangan
Herbert Fuchs
Henry S. Friedman
James E. Herndon II.
Patrick Healy
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1711-z

Weitere Artikel der Ausgabe 2/2015

Journal of Neuro-Oncology 2/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.